AUCTORES
Globalize your Research
Short Communication
*Corresponding Author: Nasser Mikhail, Endocrinology Division, Olive View-UCLA Medical Center, David-Geffen UCLA Medical School, CA, USA.
Citation: Mikhail N., Wali S., (2023), Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes, Journal of Clinical and Laboratory Research. 6(2); DOI:10.31579/2768-0487/111
Copyright: Nasser Mikhail, Endocrinology Division, Olive View-UCLA Medical Center, David-Geffen UCLA Medical School, CA, USA.
Received: 02 August 2023 | Accepted: 16 August 2023 | Published: 01 September 2023
Keywords: retatrutide; glp-1; gip; glucagon; obesity; diabetes; tirzepatide
Retatrutide is a triple hormone agonist of the receptors of glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon that can be administered subcutaneously once a week. Different doses and escalation schedules of retatrutide were evaluated in 2 phase 2 American trials of subjects with obesity (n=338) and type 2 diabetes (n=281). In the obesity trial of 48 week-duration, percentage change in body weight from baseline after 24 weeks and 48 weeks were the primary and secondary outcomes respectively. At 24 weeks, mean percentage decrease in weight ranged from 7.2perencetage to 17.5perencetage across retatrutide groups versus 1.6perencetage with placebo. At 48 weeks, the decrease was 8.7perencetage to 24.2perencetage versus 2.1perencetage with placebo. In the diabetes trial, the primary endpoint was change in glycated hemoglobin (HbA1c) values from baseline to week 24. This trial included an active treatment group receiving dulaglutide 1.5 mg once weekly. Secondary endpoints included change in HbA1c and body weight at 36 weeks. At 24 weeks, mean HbA1c reductions was 0.43perencetage to 2.02perencetage with retatrutide, 1.4perencetage with dulaglutide and 0.01perencetage with placebo. At 36 weeks, mean percentage weight reductions were 3.2perencetage to 16.9perencetage with retatrutide, 2.0perencetage with dulaglutide and 3.0perencetagewith placebo. While the decrease in HbA1c levels reached a plateau at 24 weeks, weight loss in the 2 studies was progressive without evidence of attenuation effect up to the end of follow-up at 36-48 weeks. The most common adverse effects of retatrutide were gastrointestinal (GI) such as nausea, diarrhea, vomiting and constipation reported by 13-50perencetage in the retatrutide groups compared with 35perencetagein the dulaglutide group, and 13perencetage in the placebo group. Discontinuation rates due to adverse effects were also higher with retatrutide being 16-17perencetage compared with 2perencetage with dulaglutide and 0-4perencetage with placebo. In summary, retatrutide is highly effective drug in causing substantial weight loss and HbA1c reduction. Yet, tolerance to this drug seems sub-optimal. Phase 3 trials are urgently needed to clarify efficacy and safety of retatrutide.
Retatrutide (LY3437943) is a novel triple agonist of the 3 receptors GLP-1, GIP, and glucagon [1]. Compared to the native hormones, retatrutide shows 2.9-fold less potency at the glucagon receptor (GCCR), 2.5-fold less potency at the GLP-1 receptor, and 8.9-fold greater potency at human GIP receptor [1]. The approximate half-life of retatrutide is approximately 6 days making it suitable for once weekly administration [2]. Pre-clinical studies and phase 1 trials showed that retatrutide was highly effective in promoting weight loss and lowering HbA1c levels [1,2]. Recently, 2 phase 2 studies designed to examine efficacy and safety of retatrutide for treatment of obesity and type 2 diabetes were published (table 1) [3,4]. The main purpose of this article is to provide an appraisal about this novel agent based on available data.
| Obesity trial [3] | Type 2 diabetes trial [4] | |
| Design | Double-blind, randomized, placebo-controlled, 7 groups, in the USA | Double-blind, double-dummy, randomized, placebo-controlled, 8 groups, in the USA |
| Study duration | 48 weeks | 36 weeks |
| Subjects | N=338, mean age 48.2 years, 48% women, 88% Whites, 35% Hispanics | N=281, mean age 56.2 years, 56% women, 84% Whites, 47% Hispanics |
| Baseline mean body weight and BMI | 107.7 kg and 37.3 kg/m2 | 98.2 kg and 35.0 kg/m2 |
| Baseline HbA1c | 5.6% | 8.3% |
| Intervention | Retatrutide 1 mg, 4 mg (starting dose 2 mg), 4 mg (starting dose 2 mg), 8 mg (starting dose 2 mg), 8 mg (starting dose 4 mg), or 12 mg (starting dose 2 mg) subcutaneously once a week vs placebo | Retatrutide 0.5 mg, 4 mg (starting dose 2mg), 4 mg (no escalation), 8 mg (starting dose 2 mg), 8 mg (starting dose 4 mg), or 12 mg (starting dose 2 mg), 1.5 mg dulaglutide, or placebo |
| Primary end point | Percentage change in weight from baseline to 24 weeks | Change in HbA1c from baseline to week 24 |
| Secondary endpoints | Percentage change in weight from baseline to 48 weeks, weight reduction of ≥5%, ≥10%, or ≥15% | Change in HbA1c and weight from baseline to week 36 |
| Effect of retatrutide on weight | At 24 weeks: -7.2% to -17.5% with retatrutide vs -1.6% with placebo. At 48 weeks: -8.7% to -24.2% with retatrutide vs -2.1% with placebo | At 36 weeks: -3.2% to -16.9% with retatrutide vs -2.0% with dulaglutide, and -3.0% with placebo |
| Effect of retatrutide on HbA1c levels | At 24 weeks: -0.1% to -0.4% vs +0.1% with placebo | At 24 weeks: -0.43% to -2.02% with retatrutide vs -1.41% with dulaglutide, and –0.01% with placebo |
| Drug discontinuation rates due to adverse effects | 7-16% with retatrutide vs 0% with placebo | 0-17% with retatrutide vs 2% with dulaglutide vs 4% with placebo |
| Supraventricular arrhythmias and cardiac conduction disorders | 4-14% with retatrutide vs 3% with placebo | 4-8% with retatrutide, 4% with dulaglutide, 2% with placebo |
Abbreviations in the table: BMI: body mass index, HbA1c: glycated hemoglobin.
Table 1: Overview of phase 2 trials of retatrutide for treatment of obesity and type 2 diabetes.
Retatrutide for treatment of obesity
Retatrutide, in different subcutaneous doses of 1, 4, 8 and 12 mg and escalation schedules, was evaluated for treatment of obesity in a phase 2, randomized, placebo-controlled, double-blind trial of 48 week-duration in the USA (table 1) [3]. Contrary to most preceding obesity trials that predominantly enrolled women, this study included 51.8% men [3]. Participants (n=338) had mean age of 48.2 years, and mean baseline weight of 107.7 kg, and body mass index (BMI) of 37.3 kg/m2 (table 1) [3]. All subjects received lifestyle intervention including regular counseling sessions [3]. At 24 weeks, mean percentage decrease in weight (primary outcome) ranged from 7.2% to 17.5% with different retatrutide doses compared with 1.6% with placebo. At 48 weeks, there was progressive decrease in weight (secondary outcome) ranging from 8.7% to 24.2% with retatrutide versus 2.1% with placebo [3]. Weight loss was dose-related between retatrutide doses of 1 to 8 mg. However, the difference in weight loss between the highest 2 doses, 8 and 12 mg, was minimal [3]. Inspection of the trajectory of weight loss with time showed that weight loss with retatrutide was evident after 4-8 weeks and progressed with no evidence of plateau to the end of follow-up at 48 weeks [3]. At 48 weeks, weight reduction of ≥15% was achieved by 75-83% of subjects who received 8-12 mg dose of retatrutide. Interestingly, women and subjects with BMI of ≥35 kg/m2 had more weight loss than men and subjects with BMI < 35>
Retatrutide for treatment of type 2 diabetes
In another phase 2 trial in the USA, retatrutide was evaluated for treatment of type 2 diabetes in comparison with subcutaneous dulaglutide (1.5 mg/weekly) and placebo (table 1) [4]. Study duration was 36 weeks. The primary outcome was change in HbA1c values from baseline to 24 weeks, whereas secondary endpoints were changes in HbA1c and weight after 36 weeks (table 1) [4]. Patients (n=281, 56% women, mean age 56 years) had type 2 diabetes of approximately 8 year-duration uncontrolled on metformin
with mean baseline HbA1c of 8.3% [4]. At 24 weeks, reductions in HbA1c levels were dose-related in the retatrutide groups ranging from 0.43 to 2.02%, versus 1.31% in the dulaglutide group and 0.01% in the placebo group [4]. HbA1c reductions were significantly greater with the 2 retatrutide highest doses (8 mg given in slow escalation and 12 mg/week) than with dulaglutide (P<0>
Effects of retatrutide on cardiovascular risk factors
Amelioration of several cardiovascular risk factors, mainly due to weight loss, was observed with retatrutide treatment [3,4]. In the obesity study, 72% of the participants who had prediabetes at baseline in the retatrutide groups reverted to normoglycemia (HbA1C < 5>
Safety of retatrutide
In the 2 phase 2 trials, 16-17% discontinued retatrutide compared with 0-4% with placebo due to adverse effects (table 1) [3,4]. In general, safety profile of retatrutide mimics that of incretin-based drugs with GI adverse effects being the most common in incidence and the most frequent cause of drug discontinuation. GI adverse effects (nausea, diarrhea, vomiting and constipation) were dose-related and occurred mainly during the early dose escalation period [3,4]. In the obesity trial, proportions of subjects reporting nausea were 14-60% with retatrutide versus 11% with placebo [3]. In the diabetes study, GI adverse effects were reported by 13-50% in the retatrutide group, 35% in the dulaglutide group, and 13% in the placebo group [4]. This relatively high rate of GI adverse effect may be attributed to the glucagon receptor agonism component of retatrutide. In fact, glucagon has been shown to slow gastric emptying and inhibit GI motility [5].
Effect of retatrutide on heart rate
Increase in heart rate, of approximately 2-6 beats per minute (bpm) compared with placebo, was observed with use of all GLP-1 receptor agonists and with the dual GLP-1/GIP receptor agonist tirzepatide [6-11]. However, this adverse effect did not result in increase in cardiovascular events in dedicated randomized trials [7,8]. With retatrutide, the increase in heart rate peaked 24 weeks after starting treatment and partially declined thereafter [3,4]. Placebo-adjusted increase in heart rate by retatrutide was 5.6 bpm in the obesity trial at 48 weeks and 7.5 bpm in the diabetes trial after 36 weeks [3]. In the latter study, corresponding increase was 5 bpm with dulaglutide. Furthermore, cardiac arrhythmias occurred in 4-14% and 2-3% in the retatrutide groups and placebo group, respectively in the 2 trials [3,4]. The increase in heart rate by teratrutide could be mediated in part by glucagon receptor agonism. Indeed, most, but not all, studies have shown that glucagon administration increases heart rate acutely in humans [12].
Advantages of retatrutide
The major advantage of teratrutide is its high efficacy for weight loss that exceeds efficacy of all available anti-obesity drugs. The dual GLP-1 and GIP agonist tirzepatide is currently considered the most effective drug to lower HbA1c levels and promote weight loss [10,11]. While no direct comparison between retatrutide and tirzepatide is available and duration of use is different (36-48 weeks with retatrutide versus 72 weeks with tirzepatide), retatrutide may be superior to tirzepatide in both parameters, particularly weight loss (table 2) [3,4,10,11].
| Retatrutide [3,4] | Tirzepatide [10,11] | |
| Maximum percentage weight loss in obese subjects without diabetes | 24.2% vs 2.1% placebo at 48 weeks. Difference 22.1% [3] | 20.9% vs 3.1% placebo at 72 weeks. Difference 17.8% [11] |
| Maximum weight loss in patients with type 2 diabetes | 16.9% vs 3.0% placebo at 36 weeks. Difference 13.9% [4] | 12.8% vs 3.2% placebo at 72 weeks. Difference 9.6% [11] |
| Maximum HbA1c reduction in patients with type 2 diabetes | 2.02% vs 0.01% placebo at 36 weeks. Difference 2.01% [4] | 2.1% vs 0.5% placebo at 72 weeks. Difference 1.6% [11] |
Abbreviations: HbA1c; glycated hemoglobin.
Table 2. Efficacy of retatrutide and tirzepatide in treatment of obesity and type 2 diabetes Furthermore, the difference.
in efficacy of weight reduction between the 2 agents may become even greater with more prolonged use of teratrutide beyond 48 weeks. This enhanced efficacy of retatrutide in promoting weight loss is most likely mediated through glucagon receptor agonism. In fact, Goscun et al [1] have shown that retatrutide caused weight loss in obese mice by increasing energy expenditure through glucagon receptor engagement. Moreover, a phase 1 study has shown that retatrutide may decrease appetite and increase sensation of fullness and satiety in patients with type 2 diabetes [2]. Decreased appetite was reported by 11-31% among retatrutide-treated subjects (vs 9% placebo) in the obesity trial and by 10% (vs 2% placebo) in the diabetes trial [3,4].
The main limitation of retatrutide is the high frequency rates of discontinuation due to adverse effects reaching 17% with the highest doses. These rates are much higher than the 7% discontinuation rate reported with the highest dose of tirzepatide (15 mg/week) versus 4% with placebo [10]. Since most GI adverse effects occurred during retatrutide dose escalation, the use of smaller starting doses and slower titration might decrease the incidence of GI adverse effects. In addition, the increase in pulse rate and arrhythmias is concerning and should be inspected thoroughly in pending trials, preferably using Holter monitoring of heart rate.
No doubt, retatrutide is a promising novel tri-agonist of receptors of the 2 incretins GLP-1 and GIP and glucagon. This drug showed high efficacy in causing weight loss not previously recorded with any anti-obesity agent. Additionally, its efficacy for treatment of type 2 diabetes is at least comparable to tirzepatide (table 2). Meanwhile, tolerance to retratrutide may be suboptimal with unacceptable high discontinuation rates due to adverse effects. Moreover, there are signals of increase incidence of cardiac arrhythmias associated with its use. Ongoing large-scale phase 3 trials should clarify efficacy and safety of retratrutide in subjects with obesity and type 2 diabetes. In addition, adequately powered and long-term (at least 3 years) studies designed to see the effects of retatrutide on cardiovascular events and mortality should be conducted.
The authors have no conflict of interest to declare.
Nil.
Nil.
Nil.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
